DBV Technologies is a global clinical stage biopharmaceutical company that was founded by pediatricians with a vision of treating food allergies safely and effectively. They are dedicated to advancing epicutaneous immunotherapy using their innovative technology platform called Viaskin™. This platform aims to develop new treatment options for immunologic diseases with significant unmet medical needs.

DBV Technologies' primary focus is on Viaskin™, specifically in addressing food allergies, which affects millions of patients worldwide. They are currently investigating the use of Viaskin™ for the treatment of peanut allergy and hope to offer the first epicutaneous immunotherapy treatment for this condition. In addition to food allergies, they are also exploring the potential applications of Viaskin™ for patients suffering from inflammatory and autoimmune diseases.

With a commitment to patients and their families, DBV Technologies is at the forefront of exploring and developing new therapies to improve lives